I. The introduction The systematic erythalamus (SLE) is a complex self-immuno-disease that can weigh on multiple systems and organs all over the body, with serious consequences for the quality of life and longevity of patients. Accurate clinical assessment and proper treatment are essential to improve patient prognosis because of their diverse clinical performance and complexity.
Clinical assessment (i) medical history collection For example, patients are asked whether they have common symptoms of fever, inactivity, rashes, joint pain, whether they have had a similar occurrence in the past, whether they have had a family history of their own immuno-diseases, and whether they have been exposed to environmental factors that may induce disease, such as ultraviolet exposure, and certain drugs. (ii) Medical examination. Full medical examination is essential for the assessment of SLE patients. Checks for red stains on the skin, particularly typical of a butterfly-shaped red spot (which crosses a nose beam and the cheeks of both sides resembles a butterfly), plate-shaped red spot, etc.; checks for swelling, crushing, malformation of the joint and assesses the degree of joint activity; checks for ulcer ulcer in the mouth mucous membranes; listens to the heart lungs and examines for signs related to CPR, pleura, pleura, etc.; checks for renal edema, for example, because the kidney is one of SLE ‘ s most tired and important organs.
(iii) Laboratory examination Self-antibody testing Anti-nucleus (ANA) is a screening test for SLE, and almost all SLE patients ANA are positive but less specific. Anti-twined DNA (ds-DNA) antibodies and anti-Sm antibodies have a high degree of specificity to SLE, in which the anti-ds-DNA antibodies are associated with the activity of the disease, and their drop-up is often indicative of the disease. In addition, there are a variety of self-antibodies such as anti-nuclear sugar P protein antibodies and antiteprotein antibodies, which have some value for diagnosis and assessment of the condition. Regular blood tests show a decrease in white cells, a decrease in lymphocytes, a decrease in platelets, etc. Anaemia is also more common. These haematological anomalies reflect the effects of the disease on the bone marrow blood system or the blood cell damage induced by immunization. Pee routines and kidneys check. Renal stress is one of the common and serious manifestations of SLE, and early detection of renal pathologies is important for timely treatment and improvement. The sero-remediation C3 and C4 levels are often lower and associated with disease activity. During the period of medical activity, the consumption of accompaniment is increasing and can be one of the indicators for monitoring changes in the condition. (iv) Visual examination Ultrasound examination may be used to examine the structure and functions of organs such as the heart, kidney, etc., such as the discovery of cardiac enzymes, kidneys, etc. The assessment of the related heart and kidney stress is complementary. CT and MRI can detect brain infarction, haemorrhaging, demigodosis, etc. when assessing the central nervous system; CT can be of some assistance in the diagnosis of pulmonary pathologies such as mestizo pneumonia.
Treatment (i) General treatment. Patients should avoid suntanning and use shading when going out to prevent increased UV exposure. During acute activity, care is taken to rest, to avoid fatigue and to actively control the infection in case of infection. At the same time, psychological support is provided to help the patient alleviate the psychological stress caused by the disease. (ii) Drug treatment Sugar cortex hormones are the basic drug for SLE treatment, with different doses to be selected depending on the severity of the condition. For light SLEs, small dosages of sugar cortex hormones (e.g., pennison 0.5 mg/kg per day) are used; for heavy SLEs, such as exhausting and important organs such as kidneys, central nervous systems, large dosages of sugar cortex hormones (e.g., piston 1 – 2 mg/kg per day) or even shock treatment (e.g., capeñol 500 – 1,000 mg/d, 3 consecutive days). Sugar cortex hormones can effectively control inflammation, but long-term use can cause multiple adverse effects, such as osteoporosis, infection, hypertension, diabetes, etc., which need to be closely monitored. Immunosuppressants are often used in conjunction with sugary cortex hormones to reduce hormone use and control conditions. cyclophosphate is one of the commonly used immunosuppressants, especially in cases of stress on important organs such as lupus kidneys, which can be administered through intravenous shock therapy. CCP is also more effective for patients with kidneys and blood systems and has relatively few adverse effects. In addition, there are immunosuppressants such as sulfur and cyclothylene, which can be selected on a patient-specific basis. The use of biological agents in SLE therapy has been increasing in recent years. The single-cloned antibodies for B lymphocyte stimuli (BLyS) reduce B cell activity and self-activation, which are more effective for SLE patients in some cases, especially those who are less responsive to traditional treatment. (iii) Treatment in special cases requires greater care for SLE patients in combination with pregnancy. When the condition is stable, the use of drugs, such as hydroxychloroquine, which have less influence on the foetus, may continue under the supervision of a doctor. For patients with severe kidney disorders, measures such as renal substitution treatment may need to be considered in addition to medication.
IV. CONCLUSION The systematic clinical assessment of erythalamus is an integrated and comprehensive process that requires an accurate diagnosis of the disease in the context of a wide range of information, including medical history, medical examination, laboratory examination and visual examination. Treatment, on the other hand, requires individualized choice of treatment based on the patient ‘ s specific circumstances, balancing the efficacy of the drug with the adverse effects. As medicine continues to develop, SLE awareness and treatment are also improving, and it is expected that this will further improve patient expectations and improve their quality of life.
